Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. (21st December 2015)

• Record Type: Journal Article
• Authors: Sysa-Shah, Polina; Tocchetti, Carlo G.; Gupta, Manveen; Rainer, Peter P.; Shen, Xiaoxu; Kang, Byung-Hak; Belmonte, Frances; Li, Jian; Xu, Yi; Guo, Xin; Bedja, Djahida; Gao, Wei Dong; Paolocci, Nazareno; Rath, Rutwik; Sawyer, Douglas B.; Naga Prasad, Sathyamangla V.; Gabrielson, Kathleen
• Is Part Of: Cardiovascular research. Volume 109:Number 3(2016)
• Page Start: 358
• Page End: 373
• Publication Date: 2015-12-21
• Subjects: ErbB2 -- ErbB2 kinase inhibitors -- β-Adrenergic stimulation -- β-Blockers; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Periodicals; 616.1
• DOI: 10.1093/cvr/cvv274
• Languages: English
• ISSNs: 0008-6363

Abstract

Abstract: Aims: Despite the observation that ErbB2 regulates sensitivity of the heart to doxorubicin or ErbB2-targeted cancer therapies, mechanisms that regulate ErbB2 expression and activity have not been studied. Since isoproterenol up-regulates ErbB2 in kidney and salivary glands and β2AR and ErbB2 complex in brain and heart, we hypothesized that β-adrenergic receptors (AR) modulate ErbB2 signalling status. Methods and results: ErbB2 transfection of HEK293 cells up-regulates β2AR, and β2AR transfection of HEK293 up-regulates ErbB2. Interestingly, cardiomyocytes isolated from myocyte-specific ErbB2-overexpressing (ErbB2 tg ) mice have amplified response to selective β2-agonist zinterol, and right ventricular trabeculae baseline force generation is markedly reduced with β2-antagonist ICI-118 551. Consistently, receptor binding assays and western blotting demonstrate that β2ARs levels are markedly increased in ErbB2 tg myocardium and reduced by EGFR/ErbB2 inhibitor, lapatinib. Intriguingly, acute treatment of mice with β1- and β2-AR agonist isoproterenol resulted in myocardial ErbB2 increase, while inhibition with either β1- or β2-AR antagonist did not completely prevent isoproterenol-induced ErbB2 expression. Furthermore, inhibition of ErbB2 kinase predisposed mice hearts to injury from chronic isoproterenol treatment while significantly reducing isoproterenol-induced pAKT and pERK levels, suggesting ErbB2's role in transactivation in the heart. Conclusion: Our studies show that myocardial ErbB2 and βAR signalling are linked in a feedback loop with βAR activation leading to increased ErbB2 expression and activity, and increased ErbB2 activity regulating β2AR expression. Most importantly, ErbB2 kinase activity is crucial for cardioprotection in the setting of β-adrenergic stress, suggesting that this mechanism is important in the pathophysiology and treatment of cardiomyopathy induced by ErbB2-targeting antineoplastic drugs.